Head of CMC – Lytix Biopharma

  • Denne stillingen er besatt

Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic peptide with the potential to personalize immunotherapy. LTX-315 is administered intratumorally and works by inducing lysis of intracellular organelles of tumor cells such as mitochondria, thereby unleashing a broad spectrum of tumor antigens for T cell responses. LTX-315 effectively kills not only therapy tumor cells, but also therapy resistant and stem cell-like tumor cells, invoking broad personal T cell responses, in both the tumor and blood. Clinical trials have shown an increase in CD8+ T cell infiltration and clinical abscopal effects. The company strategy is to utilize this T cell response as a primer to enhance and boost patient specific and tumor associated antigens as part of an adoptive transfer regimen aiming to tackle tumor heterogeneity.

Head of CMC


The responsibilities of the position CMC include, but are not limited to:

  • Work with CMC consultants as appropriate to deliver Lytix CMC projects
  • Managing CMC documentation in accordance with QMS requirements
    • Reports
    • Agreements (like quality agreements)
  • Managing LTX-315 CMC responsibility with Verrica Pharmaceuticals Inc
    • API supply
      • Quantities (supply forecasts)
      • Retest
      • Stability
    • DP supply
      • Quantities (supply forecasts)
      • Stability
      • Shelf-life management
  • Managing LTX-315 Lytix development
    • API management at Bachem (CMO)
    • DP management
  • Managing LTX-401 development
    • API development
    • DP development
  • Ordering and handling immune checkpoint inhibitors for use in next clinical study


Workplace is Oslo, Norway


For more information, please contact external recruiter, Borka Consulting AS:

The recruitment process is carried out in collaboration with the consulting company Borka Consulting AS.

If you would like to find out more about this position, please do not hesitate to contact Andre Borka (+47 908 31 871) or Cecilie Borka (+47 928 55 352)

Please send your application (both motivational letter and CV) in PDF format to andre@borka.no.
Selection will be ongoing, please apply and with your CV and motivational letter as soon as possible!
All inquiries are treated confidentially.


More information about:
Lytix Biopharma at www.lytixbiopharma.com
Agreement with Verrica Pharmaceuticals at www.lytixbiopharma.com/news/432/130/Lytix-Biopharma-enters-milestone-agreement-with-Verrica-Pharmaceuticals-for-its-lead-candidate-LTX-315.html


Del dette: